[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity'(NEDA-4) in relapsing–remitting multiple sclerosis
Background:'No evidence of disease activity'(NEDA), defined as absence of magnetic
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …
“No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis
G Giovannoni, D Tomic, JR Bright… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Using combined endpoints to define no evident disease activity (NEDA) is becoming
increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS) …
increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS) …
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines
With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …
Treatment optimization in MS: Canadian MS Working Group updated recommendations
The Canadian Multiple Sclerosis Working Group (CMSWG) developed practical
recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying …
recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying …
[HTML][HTML] Use of natalizumab in persons with multiple sclerosis: 2022 update
SA Morrow, F Clift, V Devonshire, E Lapointe… - Multiple Sclerosis and …, 2022 - Elsevier
Background Natalizumab is a humanized monoclonal antibody used for treatment of highly
active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing …
active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing …
[HTML][HTML] Optimizing therapy early in multiple sclerosis: an evidence-based view
Therapies that target the underlying pathology of multiple sclerosis (MS), including focal and
diffuse damage, may improve long-term disease control. Focal damage (inflammatory …
diffuse damage, may improve long-term disease control. Focal damage (inflammatory …
No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: Clinician and patient perspectives [Narrative Review]
SD Newsome, C Binns, UW Kaunzner, S Morgan… - Neurology and …, 2023 - Springer
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …